CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 139 filers reported holding CRINETICS PHARMACEUTICALS IN in Q2 2023. The put-call ratio across all filers is 19.18 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,106,536 | +43.5% | 37,207 | -13.1% | 0.00% | 0.0% |
| Q2 2023 | $771,183 | +51.4% | 42,796 | +34.9% | 0.00% | 0.0% |
| Q1 2023 | $509,424 | -6.2% | 31,720 | +6.9% | 0.00% | 0.0% |
| Q4 2022 | $543,181 | -11.1% | 29,682 | -4.5% | 0.00% | 0.0% |
| Q3 2022 | $611,000 | +19.6% | 31,066 | +13.2% | 0.00% | 0.0% |
| Q2 2022 | $511,000 | -6.6% | 27,436 | +10.1% | 0.00% | – |
| Q1 2022 | $547,000 | -5.2% | 24,930 | +22.7% | 0.00% | – |
| Q4 2021 | $577,000 | +89.8% | 20,317 | +41.3% | 0.00% | – |
| Q3 2021 | $304,000 | +13.0% | 14,382 | +0.6% | 0.00% | – |
| Q2 2021 | $269,000 | +68.1% | 14,290 | +36.2% | 0.00% | – |
| Q1 2021 | $160,000 | -38.7% | 10,492 | -43.2% | 0.00% | – |
| Q4 2020 | $261,000 | +23.7% | 18,470 | +53.2% | 0.00% | – |
| Q2 2020 | $211,000 | – | 12,057 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 3,375,169 | $76,819,000 | 7.66% |
| RA Capital Management | 1,875,209 | $42,680,000 | 1.84% |
| Perceptive Advisors | 2,587,953 | $58,901,000 | 1.66% |
| EMORY UNIVERSITY | 97,035 | $2,209,000 | 1.55% |
| New Leaf Venture Partners, L.L.C. | 167,700 | $3,817,000 | 1.05% |
| Orbimed Advisors | 1,914,282 | $43,569,000 | 0.67% |
| Opaleye Management Inc. | 73,000 | $1,661,000 | 0.46% |
| Novo Holdings A/S | 135,009 | $3,073,000 | 0.46% |
| Virtus ETF Advisers LLC | 7,934 | $181,000 | 0.38% |
| Eventide Asset Management | 384,000 | $8,740,000 | 0.30% |